<DOC>
	<DOC>NCT01697696</DOC>
	<brief_summary>The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.</brief_summary>
	<brief_title>Long Term Safety Study of NVA237 vs QAB149 in COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1. Male or female patients with COPD according to GOLD 2011 who have signed informed consent. 2. Patients with airflow limitation of 3080% postbronchodilator FEV1 at runin. 3. Current or exsmokers with a smoking history of at least 10 pack years 4. Patients with a mMRC score of at least 2 at runin. 1. Patients contraindicated for muscarinic antagonist agents and beta2 agonists 2. Patients with a history of malignancy of any organ system, treated or untreated, within the last five years 3. Patients with narrowangle glaucoma, BPH or bladderneck obstruction or moderatesevere renal impairment or urinary retention 4. Patients who had a COPD exacerbation within 6 weeks prior to screening. 5. Patients requiring long term oxygen therapy prescribed for more than 12 hr per day. 6. Patients with a history of asthma. 7. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to 40 years of age. 8. Patients with a blood eosinophil count of greater than 600 mm/3 during runin 9. Patients with concomitant pulmonary disease 10. Patients with a history of certain cardiovascular comorbid conditions 11. Patients with a diagnosis of alpha1 antitrypsin deficiency 12. Patients with active pulmonary tuberculosis 13. Patients in the active phase of a pulmonary rehabilitation programme 14. Other protocoldefined inclusion / exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD, NVA237, QAB149, glycopyrronium bromide</keyword>
</DOC>